74 filings
Page 3 of 4
8-K
8auq6
15 May 20
Departure of Directors or Certain Officers
4:34pm
8-K
964bi1on7yz iemg
11 May 20
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
4:38pm
8-K
b04bc1jof616bao9ybzs
26 Mar 20
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
7:39am
8-K
r9eiof
20 Mar 20
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25
7:40am
8-K
f4g vpxaz5lmeu0rz
16 Mar 20
Other Events
7:30am
8-K
60cn9ka
10 Mar 20
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
et42sj 5mdcfiw7
9 Mar 20
Other Events
4:30pm
8-K
ixe0rpckvo1k9we
2 Mar 20
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
8:50am
8-K
aurur5fo60g w6016hz
29 Jan 20
Other Events
7:13am
8-K
0mfx so7pwkq881mq2
17 Jan 20
Termination of a Material Definitive Agreement
4:50pm
8-K
3nf2vl
13 Jan 20
Regulation FD Disclosure
7:42am
8-K
jkbyhgstp41hr
6 Jan 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:32pm
8-K
40zebt7wtnb8nyikih
9 Dec 19
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting
7:00am
8-K
enljrfao
12 Nov 19
Unum Therapeutics Reports Third Quarter 2019 Financial Results
4:36pm
8-K
31rsvi00
5 Nov 19
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
2:16pm
8-K
fdq4h8pxs55c1 8w3
4 Nov 19
Unum Therapeutics Announces Strategic Focus on DevelopingBest-in-Class
4:13pm
8-K
lp06y 3jp
12 Aug 19
Unum Therapeutics Reports Second Quarter 2019 Financial Results
4:12pm
8-K
xmb1i2
5 Aug 19
Entry into a Material Definitive Agreement
5:27pm
8-K
df4qhatn6g0gr6kuo7
29 Jul 19
Unum Therapeutics Announces New Appointments to its Board of Directors
7:24am
8-K
o6dkvfqf04 maou9x
25 Jul 19
Departure of Directors or Certain Officers
4:47pm